Performing allogeneic and autologous hematopoietic SCT in the outpatient setting: Effects on infectious complications and early transplant outcomes

Bone Marrow Transplantation

Volumn 45, Issue 7, 2010, Pages 1220-1226

  Mcdiarmid, S ^a   Hutton, B ^b   Atkins, H ^a   Bence Bruckler, I ^a   Bredeson, C ^c   Sabri, E ^b   Huebsch, L ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; CEFTAZIDIME; CEFTRIAXONE; COTRIMOXAZOLE; CYCLOSPORIN A; ENOXAPARIN; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; PIPERACILLIN PLUS TAZOBACTAM; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; COHORT ANALYSIS; CONTROLLED STUDY; FEBRILE NEUTROPENIA; FEMALE; GRAFT VERSUS HOST REACTION; HOSPITAL PATIENT; HUMAN; INCIDENCE; INFECTION COMPLICATION; LENGTH OF STAY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE MYELOMA; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; OUTPATIENT; PNEUMOCYSTOSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VEIN OCCLUSION; ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; CHILD; COMPARATIVE STUDY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INFECTION; OPPORTUNISTIC INFECTIONS; TIME; TREATMENT OUTCOME;

ADULT; CHILD; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; INFECTION; MALE; OPPORTUNISTIC INFECTIONS; OUTPATIENTS; RETROSPECTIVE STUDIES; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 77955013674     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.330     Document Type: Article

References (31)

1. Hayes-Lattin B, Leis JF, Maziarz RT. Isolation in the allogeneic transplant environment: how protective is it? Bone Marrow Transplant 2005; 36: 373-381.
2. Peters WP, Ross M, Vredenburgh JJ, Hussein A, Rubin P, Dukelow K et al. The use of intensive clinic support to permit outpatient autologous bone marrow transplantation for breast cancer. Semin Oncol 1994; 21: 25-31.
3. Dix SP, Geller RB. High-dose chemotherapy with autologous stem cell rescue in the outpatient setting. Oncology 2000; 13: 171-192.
4. Morabito F, Martino M, Stelitano C, Oliva E, Kropp M, Irrera G et al. Feasibility of a mixed inpatient-outpatient model of peripheral blood stem cell transplantation for multiple myeloma. Haematologica 2002; 87: 1192-1199.
5. Meisenberg BR, Miller WE, McMillan R, Callaghan M, Sloan C, Brehm T et al. Outpatient high-dose chemotherapy with autologous stem-cell rescue for hematologic and non-hematologic malignancies. J Clin Oncol 1997; 15: 11-17.
6. Meisenberg BR, Kerran K, Hollenbach K, Brehm T, Jollon J, Piro LD. Reduced charges and costs associated with outpatient autologous stem cell transplantation. Bone Marrow Transplant 1998; 21: 927-932.
7. Gluck S, Des Rochers C, Cano C, Dorreen M, Germond C, Gill K et al. High-dose chemotherapy followed by autologous blood cell transplantation: a safe and effective outpatient approach. Bone Marrow Transplant 1997; 20: 431-434.
8. Jagannath S, Vesole DH, Zhang M, Desikan KR, Copeland N, Jagannath M et al. Feasibility and cost-effectiveness of outpatient autotransplants in multiple myeloma. Bone Marrow Transplant 1997; 20: 445-450.
9. Russell JA, Poon MC, Jones AR, Woodman RC, Ruether B. Allogeneic bone marrow transplantation for adults with malignancy without protective isolation. Lancet 1992; 339: 38-40.
10. Russell JA, Chaudhry A, Booth K, Brown C, Woodman RC, Valentine K et al. Early outcomes after allogeneic stem cell transplantation for leukemia and myelodysplasia without protective isolation: a 10-year experience. Biol Blood Marrow Transplant 2000; 6: 109-114.
11. van Tiel FH, Harbers MM, Kessels AG, Schouten HC. Home care vs hospital care of patients with hematological malignancies and chemotherapy-induced cytopenia. Ann Oncol 2005; 16: 195-205.
12. Svahn BM, Remberger M, Myrback KE, Holmberg K, Eriksson B, Hentschke P et al. Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared with hospital care. Blood 2002; 100: 4317-4324.
13. Petersen SL, Madsen HO, Ryder LP, Jakobsen BK, Sengelv H, Heilmannet C et al. Haematopoietic stem cell transplantation with non-myeloablative conditioning in the outpatient setting: results, complications and admission requirements in a single institution. Br J Haematol 2004; 125: 225-231.
14. Crump MC, Brandwein JM, Smith AM, Langley GR, Burnell MJ, Huebsch L et al. A regional autologous bone marrow transplant network: transfers to designated centers on the day after transplant. Bone Marrow Transplant 1992; 9: 445-450.
15. Bredeson C, Perry G, Martens C, McDiarmid S, Bence- Bruckler I, Atkins H et al. Outpatient total body irradiation as a component of a comprehensive outpatient transplant program. Bone Marrow Transplant 2002; 29: 667-671.
16. Leger C, Sabloff M, McDiarmid S, Bence-Bruckler I, Atkins H, Bredeson C et al. Outpatient autologous hematopoietic stem cell transplantation for patients with relapsed follicular lymphoma. Ann Hematol 2006; 85: 723-729.
17. McDiarmid C, Hamelin L, Huebsch L. Leading change: retrospective evaluation of a nurse-led initiative from Hickman catheters to peripherally inserted central catheters as the vascular access option for autologous stem cell transplant recipients. J Infusion Nursing 2006; 29: 81-88.
18. Bence-Bruckler I, Bredeson C, Atkins H, McDiarmid S, Hamelin L, Hopkins H et al. A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation. Bone Marrow Transplant 1998; 22: 965-969.
19. Khaliq Y, Bence-Bruckler I, Bredeson C, van der Jagt R, McDiarmid S, Huebsch L. Once daily Ceftriaxone for febrile neutropenia in an outpatient blood and marrow transplant program. Blood 1996; 86(Suppl 1) 212A: 837
20. West F, Mitchell S. Evidence-based guidelines for the management of neutropenia following outpatient hematopoietic stem cell transplantation. Clinical J Oncol Nursing 2004; 8: 601-613.
21. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2000; 6: 659-713, 715, 717-727.
22. Dykewicz CA. Preventing opportunistic infections in bone marrow transplant recipients. Transplant Infectious Diseases 1999; 1: 40-49.
23. Walter EA, Bowden RA. Infection in the bone marrow transplant recipient. Infect Dis Clin N Am 1995; 9: 823-847.
24. Petersen F, Thornquist M, Buckner C, Counts G, Nelson N, Meyers J et al. The effects of infection prevention regimens on early infectious complications in marrow transplant patients: a four arm randomized study. Infection 1988; 16: 199-208.
25. Passweg JR, Rowlings PA, Atkinson KA, Barrett AJ, Gale RP, Gratwohl A et al. Influence of protective isolation on outcome of allogeneic bone marrow transplantation for leukemia. Bone Marrow Transplant 1998; 21: 1231-1238.
26. Huebsch L, Gonsalves C, McCarthy A, McDiarmid S. The impact of infections in bone marrow transplant recipients treated in an outpatient setting. Bone Marrow Transplant 35 (Suppl 2) (abstract P633): 84.
27. Weinstein MP. Current blood culture methods and systems: clinical concepts, technology, and interpretation of results. Clin Infect Dis 1996; 23: 40-60.
28. Adamkiewicz TV, Lorenzana A, Doyle J, Richardson S. Peripheral vs central blood cultures in patients admitted to a pediatric oncology ward. Pediatr Infect Dis J 1999; 18: 556-558.
29. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. CID 2002; 34: 730-751.
30. Karthaus M, Cornely OA. Ceftriaxone in febrile neutropenia. J Chemother 2003; 15: 211-219.
31. McDiarmid S, Bredeson C, Huebsch L. Selection of appropriate venous access for the collection of peripheral blood progenitor cells by experienced apheresis nurses. J Clin Apheresis 1999; 14: 51-56.